<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936883</url>
  </required_header>
  <id_info>
    <org_study_id>H13-02139</org_study_id>
    <nct_id>NCT01936883</nct_id>
  </id_info>
  <brief_title>Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy</brief_title>
  <acronym>BrachyQOL</acronym>
  <official_title>IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BC Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal non surgical treatment of prostate cancer requires dose escalation which is
      frequently provided by adding a brachytherapy &quot;boost&quot; to a short course of external beam
      radiotherapy. The hypothesis in this randomized study is that a High Dose Rate (HDR)
      brachytherapy boost leads to equivalent or better Prostate Specific Antigen (PSA)
      recurrence-free survival when compared to a Low Dose Rate (LDR) brachytherapy boost and that
      it is associated with a more favorable toxicity profile and improved quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men with intermediate or high risk prostate cancer who are technically suitable for prostate
      brachytherapy based on prostate size and voiding function and who are interested in this
      modality of treatment will be approached for randomization between either high dose rate
      (single 15 Gray) or low dose rate permanent seed implant (110 Gray) brachytherapy. Baseline
      International Prostate Symptom score, Quality of Life Assessment and International Index of
      Erectile Function will be recorded and then every 3 months for the first year and every 6
      months to 3 years. Androgen deprivation treatment is allowed for 6 or 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life will be measured through validated instruments including International Prostate Symptom Score, the International Index of Erectile Function, and the urinary, bowel and sexual domains of EPIC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life long term</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of Life will be assessed to 3 years using the validated instruments International Prostate Symptom Score, International Index Erectile Function and EPIC</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy</measure>
    <time_frame>8 years</time_frame>
    <description>regular PSA monitoring every 6 months to 3 years and then annually to determine PSA recurrence free survival</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>LDR boost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDR boost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR</intervention_name>
    <description>High dose rate brachytherapy</description>
    <arm_group_label>HDR boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LDR</intervention_name>
    <description>Low dose rate brachytherapy boost</description>
    <arm_group_label>LDR boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper tier intermediate risk with at least 2 of the following factors

               1. Tumor-Nodes-Metastases Tumor stage T2B or greater

               2. Gleason Score 7

               3. PSA &gt; 10

               4. &gt; 50% of the biopsies positive

          -  OR High risk prostate cancer with one of the following factors

               1. T3a

               2. Gleason Score8-10

               3. PSA &gt;20

          -  Positive prostate biopsy within 6 months (reviewed centrally)

          -  International Prostate Symptom Score &lt; 16

          -  Prostate volume &lt; 60 cc

          -  Negative staging CT and Bone scan within 3 months prior to registration

          -  History and physical examination within 90 days prior to registration

          -  European Cooperative Oncology Group performance status 0-1 prior to registration

          -  Age &gt;45

          -  Patient suitable for procedure under anesthesia

        Exclusion Criteria:

          -  Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at
             least 3 years prior to registration

          -  Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for prostate
             cancer

          -  Previous pelvic irradiation or prostate brachytherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Bachand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juanita Crook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois Bachand, MD</last_name>
    <phone>250 979 6645</phone>
    <email>fbachand@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juanita M Crook, MD</last_name>
    <phone>250 979 6645</phone>
    <email>jcrook@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>British Columbia Cancer Agency Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Bachand, MD</last_name>
      <phone>250 979 6645</phone>
      <email>fbachand@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Juanita Crook, MD</last_name>
      <phone>250 979 6645</phone>
      <email>jcrook@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ross Halperin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Schmidt, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deidre Batchelar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Araujo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Petrik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Rose, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pierre Millette, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Hilts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bachand F, Martin AG, Beaulieu L, Harel F, Vigneault E. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):679-84. doi: 10.1016/j.ijrobp.2008.05.003. Epub 2008 Oct 27.</citation>
    <PMID>18963537</PMID>
  </reference>
  <reference>
    <citation>Schmid M, Crook JM, Batchelar D, Araujo C, Petrik D, Kim D, Halperin R. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. Brachytherapy. 2013 Jan-Feb;12(1):56-64. doi: 10.1016/j.brachy.2012.03.002. Epub 2012 Apr 17.</citation>
    <PMID>22513104</PMID>
  </reference>
  <reference>
    <citation>Morton GC, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305. doi: 10.1016/j.ijrobp.2010.04.046. Epub 2010 Aug 12.</citation>
    <PMID>20708853</PMID>
  </reference>
  <reference>
    <citation>Pieters BR, de Back DZ, Koning CC, Zwinderman AH. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol. 2009 Nov;93(2):168-73. doi: 10.1016/j.radonc.2009.08.033. Epub 2009 Sep 11. Review.</citation>
    <PMID>19748692</PMID>
  </reference>
  <reference>
    <citation>Deutsch I, Zelefsky MJ, Zhang Z, Mo Q, Zaider M, Cohen G, Cahlon O, Yamada Y. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy. 2010 Oct-Dec;9(4):313-8. doi: 10.1016/j.brachy.2010.02.196. Epub 2010 Aug 4.</citation>
    <PMID>20685176</PMID>
  </reference>
  <reference>
    <citation>Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33. Epub 2005 Oct 19.</citation>
    <PMID>16242258</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostatic neoplasm</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>high dose rate</keyword>
  <keyword>low dose rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

